image
Healthcare - Medical - Devices - NASDAQ - US
$ 4.67
1.74 %
$ 493 M
Market Cap
-13.74
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one MXCT stock under the worst case scenario is HIDDEN Compared to the current market price of 4.67 USD, MaxCyte, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one MXCT stock under the base case scenario is HIDDEN Compared to the current market price of 4.67 USD, MaxCyte, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one MXCT stock under the best case scenario is HIDDEN Compared to the current market price of 4.67 USD, MaxCyte, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
41.3 M REVENUE
-6.72%
-48.3 M OPERATING INCOME
-76.53%
-37.9 M NET INCOME
-60.89%
-21.7 M OPERATING CASH FLOW
-46.70%
55 M INVESTING CASH FLOW
321.50%
2.14 M FINANCING CASH FLOW
-25.81%
8.16 M REVENUE
-21.72%
-14.1 M OPERATING INCOME
-17.69%
-11.6 M NET INCOME
-23.27%
-4.39 M OPERATING CASH FLOW
9.16%
3.61 M INVESTING CASH FLOW
-81.39%
228 K FINANCING CASH FLOW
-68.02%
Balance Sheet MaxCyte, Inc.
image
Current Assets 190 M
Cash & Short-Term Investments 168 M
Receivables 5.78 M
Other Current Assets 16.1 M
Non-Current Assets 78.1 M
Long-Term Investments 42.9 M
PP&E 34.8 M
Other Non-Current Assets 388 K
Current Liabilities 17.9 M
Accounts Payable 743 K
Short-Term Debt 774 K
Other Current Liabilities 16.3 M
Non-Current Liabilities 18.3 M
Long-Term Debt 18 M
Other Non-Current Liabilities 283 K
EFFICIENCY
Earnings Waterfall MaxCyte, Inc.
image
Revenue 41.3 M
Cost Of Revenue 4.74 M
Gross Profit 36.5 M
Operating Expenses 84.8 M
Operating Income -48.3 M
Other Expenses -10.4 M
Net Income -37.9 M
RATIOS
88.51% GROSS MARGIN
88.51%
-116.98% OPERATING MARGIN
-116.98%
-91.85% NET MARGIN
-91.85%
-16.33% ROE
-16.33%
-14.14% ROA
-14.14%
-19.23% ROIC
-19.23%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis MaxCyte, Inc.
image
Net Income -37.9 M
Depreciation & Amortization 4.17 M
Capital Expenditures -3.7 M
Stock-Based Compensation 14 M
Change in Working Capital 3.82 M
Others -13 M
Free Cash Flow -25.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets MaxCyte, Inc.
image
Wall Street analysts predict an average 1-year price target for MXCT of $8 , with forecasts ranging from a low of $8 to a high of $8 .
MXCT Lowest Price Target Wall Street Target
8 USD 71.31%
MXCT Average Price Target Wall Street Target
8 USD 71.31%
MXCT Highest Price Target Wall Street Target
8 USD 71.31%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership MaxCyte, Inc.
image
Sold
0-3 MONTHS
221 K USD 3
3-6 MONTHS
554 K USD 3
6-9 MONTHS
325 K USD 2
9-12 MONTHS
22 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
489 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Jan 13, 2025
Sell 20.3 K USD
Sandoval David I.
GENERAL COUNSEL
- 4466
4.5391 USD
1 month ago
Dec 26, 2024
Sell 12 K USD
Johnston John Joseph
Director
- 3000
4.007 USD
1 month ago
Dec 06, 2024
Sell 1.87 K USD
Johnston John Joseph
Director
- 505
3.701 USD
1 month ago
Dec 09, 2024
Sell 9.46 K USD
Johnston John Joseph
Director
- 2495
3.791 USD
3 months ago
Nov 01, 2024
Sell 177 K USD
Erck Stanley C
Director
- 47689
3.72 USD
3 months ago
Oct 28, 2024
Sell 11.2 K USD
Johnston John Joseph
Director
- 3000
3.722 USD
4 months ago
Oct 01, 2024
Sell 98.6 K USD
Erck Stanley C
Director
- 26082
3.78 USD
4 months ago
Oct 02, 2024
Sell 80.2 K USD
Erck Stanley C
Director
- 21607
3.71 USD
4 months ago
Sep 26, 2024
Sell 11.5 K USD
Johnston John Joseph
Director
- 3000
3.82 USD
4 months ago
Sep 03, 2024
Sell 73.5 K USD
Erck Stanley C
Director
- 17922
4.1 USD
4 months ago
Sep 04, 2024
Sell 118 K USD
Erck Stanley C
Director
- 29767
3.97 USD
5 months ago
Aug 26, 2024
Sell 12.8 K USD
Johnston John Joseph
Director
- 3000
4.28 USD
6 months ago
Aug 01, 2024
Sell 70.3 K USD
Ross Thomas M.
EVP, GLOBAL SALES
- 15476
4.54 USD
6 months ago
Aug 02, 2024
Sell 77.9 K USD
Ross Thomas M.
EVP, GLOBAL SALES
- 17857
4.361 USD
6 months ago
Jul 26, 2024
Sell 14.2 K USD
Johnston John Joseph
Director
- 3000
4.746 USD
6 months ago
Jul 08, 2024
Sell 79.8 K USD
Ross Thomas M.
EVP, GLOBAL SALES
- 19802
4.029 USD
6 months ago
Jul 09, 2024
Sell 54.6 K USD
Ross Thomas M.
EVP, GLOBAL SALES
- 13531
4.034 USD
7 months ago
Jun 27, 2024
Sell 39.9 K USD
Johnston John Joseph
Director
- 10000
3.99 USD
7 months ago
Jun 20, 2024
Sell 136 K USD
Ross Thomas M.
EVP, GLOBAL SALES
- 33333
4.094 USD
7 months ago
Jun 10, 2024
Bought 345 K USD
Masoud Maher
President and CEO
+ 70443
4.901 USD
7 months ago
Jun 07, 2024
Bought 144 K USD
Masoud Maher
President and CEO
+ 29557
4.866 USD
10 months ago
Mar 26, 2024
Sell 22 K USD
Johnston John Joseph
Director
- 5000
4.405 USD
1 year ago
Jan 26, 2024
Sell 25.6 K USD
Johnston John Joseph
Director
- 5000
5.117 USD
1 year ago
Dec 26, 2023
Sell 22.6 K USD
Johnston John Joseph
Director
- 5000
4.53 USD
1 year ago
Dec 04, 2023
Sell 125 K USD
Doerfler Douglas
President and CEO
- 25008
5.01 USD
1 year ago
Dec 05, 2023
Sell 514 K USD
Doerfler Douglas
President and CEO
- 99442
5.17 USD
1 year ago
Dec 01, 2023
Sell 101 K USD
Doerfler Douglas
President and CEO
- 20200
5 USD
1 year ago
Nov 27, 2023
Sell 23 K USD
Johnston John Joseph
Director
- 5000
4.59 USD
1 year ago
Nov 14, 2023
Sell 37.1 K USD
Johnston John Joseph
Director
- 10000
3.71 USD
1 year ago
Aug 30, 2023
Sell 10.5 K USD
Johnston John Joseph
Director
- 2841
3.7 USD
1 year ago
Jul 26, 2023
Sell 23.8 K USD
Johnston John Joseph
Director
- 5000
4.75 USD
1 year ago
Jul 10, 2023
Sell 2.23 K USD
Doerfler Douglas
President and CEO
- 445
5.01 USD
1 year ago
Jul 11, 2023
Sell 64.5 K USD
Doerfler Douglas
President and CEO
- 12798
5.04 USD
1 year ago
Jul 12, 2023
Sell 84.1 K USD
Doerfler Douglas
President and CEO
- 16757
5.02 USD
1 year ago
Jun 26, 2023
Sell 33.8 K USD
Johnston John Joseph
Director
- 7529
4.49 USD
1 year ago
Jun 27, 2023
Sell 32.8 K USD
Johnston John Joseph
Director
- 7471
4.39 USD
1 year ago
Jun 13, 2023
Sell 75.3 K USD
Doerfler Douglas
President and CEO
- 14968
5.03 USD
1 year ago
Jun 14, 2023
Sell 146 K USD
Doerfler Douglas
President and CEO
- 28883
5.04 USD
1 year ago
May 03, 2023
Sell 81.1 K USD
Doerfler Douglas
President and CEO
- 16149
5.02 USD
1 year ago
Apr 12, 2023
Sell 27.9 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 5583
5 USD
1 year ago
Apr 12, 2023
Sell 63.6 K USD
Doerfler Douglas
President and CEO
- 12718
5 USD
1 year ago
Apr 05, 2023
Sell 34.8 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 6967
5 USD
1 year ago
Apr 06, 2023
Sell 137 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 27193
5.03 USD
1 year ago
Apr 05, 2023
Sell 34.8 K USD
Doerfler Douglas
President and CEO
- 6961
5 USD
1 year ago
Apr 06, 2023
Sell 140 K USD
Doerfler Douglas
President and CEO
- 27862
5.03 USD
1 year ago
Mar 31, 2023
Sell 13 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 2607
5 USD
1 year ago
Apr 03, 2023
Sell 501 USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 100
5.01 USD
1 year ago
Apr 04, 2023
Sell 36.5 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 7266
5.03 USD
1 year ago
Mar 31, 2023
Sell 13 K USD
Doerfler Douglas
President and CEO
- 2607
5 USD
1 year ago
Apr 03, 2023
Sell 501 USD
Doerfler Douglas
President and CEO
- 100
5.01 USD
1 year ago
Apr 04, 2023
Sell 37.6 K USD
Doerfler Douglas
President and CEO
- 7470
5.03 USD
1 year ago
Mar 29, 2023
Bought 345 K USD
DOUGLAS RICHARD
Director
+ 80000
4.3185 USD
2 years ago
Feb 01, 2023
Sell 99.7 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 17558
5.68 USD
2 years ago
Feb 02, 2023
Sell 66.8 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 11575
5.77 USD
2 years ago
Feb 01, 2023
Sell 110 K USD
Doerfler Douglas
President and CEO
- 19335
5.69 USD
2 years ago
Feb 02, 2023
Sell 61.5 K USD
Doerfler Douglas
President and CEO
- 10665
5.77 USD
2 years ago
Jan 05, 2023
Sell 51.6 K USD
Doerfler Douglas
President and CEO
- 10234
5.04 USD
2 years ago
Jan 05, 2023
Sell 47.7 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 9467
5.04 USD
2 years ago
Dec 05, 2022
Sell 79 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 14133
5.59 USD
2 years ago
Nov 02, 2022
Sell 39.1 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 5704
6.85 USD
2 years ago
Oct 11, 2022
Sell 27.9 K USD
Ross Thomas M.
EVP, Global Sales & Marketing
- 4282
6.51 USD
2 years ago
Oct 03, 2022
Sell 4.53 M USD
Casdin Eli
Director
- 735786
6.15 USD
2 years ago
Oct 03, 2022
Sell 4.53 M USD
Casdin Partners Master Fund, L.P.
10 percent owner
- 735786
6.15 USD
2 years ago
Jul 01, 2022
Sell 13.9 M USD
Casdin Eli
director:
- 3235548
4.3 USD
2 years ago
Jul 01, 2022
Sell 13.9 M USD
Casdin Partners Master Fund, L.P.
10 percent owner
- 3235548
4.3 USD
3 years ago
Nov 22, 2021
Bought 222 K USD
DOUGLAS RICHARD
Director
+ 20000
11.12 USD
3 years ago
Nov 12, 2021
Sell 326 K USD
Masoud Maher
EVP and General Counsel
- 25722
12.66 USD
3 years ago
Nov 15, 2021
Sell 374 K USD
Masoud Maher
EVP and General Counsel
- 30716
12.16 USD
3 years ago
Nov 16, 2021
Sell 224 K USD
Masoud Maher
EVP and General Counsel
- 18562
12.08 USD
3 years ago
Nov 12, 2021
Sell 647 K USD
Murphy Amanda Louise
Chief Financial Officer
- 51103
12.66 USD
3 years ago
Nov 15, 2021
Sell 749 K USD
Murphy Amanda Louise
Chief Financial Officer
- 61591
12.16 USD
3 years ago
Nov 16, 2021
Sell 451 K USD
Murphy Amanda Louise
Chief Financial Officer
- 37306
12.08 USD
3 years ago
Nov 12, 2021
Sell 539 K USD
Ross Thomas M.
EVP, Global Sales
- 42590
12.66 USD
3 years ago
Nov 15, 2021
Sell 624 K USD
Ross Thomas M.
EVP, Global Sales
- 51352
12.16 USD
3 years ago
Nov 16, 2021
Sell 376 K USD
Ross Thomas M.
EVP, Global Sales
- 31163
12.08 USD
3 years ago
Nov 12, 2021
Sell 588 K USD
Holtz Ron
SVP and CAO
- 46485
12.65 USD
3 years ago
Nov 15, 2021
Sell 783 K USD
Holtz Ron
SVP and CAO
- 64385
12.16 USD
3 years ago
Nov 16, 2021
Sell 473 K USD
Holtz Ron
SVP and CAO
- 39130
12.08 USD
3 years ago
Nov 12, 2021
Sell 1.29 M USD
Doerfler Douglas
President and CEO
- 101847
12.66 USD
3 years ago
Nov 15, 2021
Sell 1.5 M USD
Doerfler Douglas
President and CEO
- 123263
12.16 USD
3 years ago
Nov 16, 2021
Sell 905 K USD
Doerfler Douglas
President and CEO
- 74890
12.08 USD
3 years ago
Jul 30, 2021
Bought 23.4 M USD
Casdin Partners Master Fund, L.P.
10 percent owner
+ 1800000
13 USD
7. News
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 weeks ago
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 weeks ago
MaxCyte Announces Retirement of Board Member Art Mandell ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte's growth and strategic direction. Upon Mr. Mandell's retirement, MaxCyte will have nine directors. globenewswire.com - 1 month ago
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations, the company made adjustments to its workforce which affected 21 positions, reflecting approximately 15% of its personnel globally, including both directly employed individuals and those engaged through third-party employer-of-record (EOR) arrangements. This adjustment is designed to improve accountability, better align personnel resources with the company's goals, and position MaxCyte for long-term growth. globenewswire.com - 1 month ago
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects globenewswire.com - 2 months ago
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript seekingalpha.com - 2 months ago
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago. zacks.com - 2 months ago
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. globenewswire.com - 2 months ago
MaxCyte to Participate in Two Upcoming Investor Conferences ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. globenewswire.com - 3 months ago
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 3 months ago
MaxCyte Appoints Cynthia Collins to its Board of Directors ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. globenewswire.com - 3 months ago
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. globenewswire.com - 3 months ago
8. Profile Summary

MaxCyte, Inc. MXCT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 493 M
Dividend Yield 0.00%
Description MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Contact 9713 Key West Avenue, Rockville, MD, 20850 https://maxcyte.com
IPO Date July 30, 2021
Employees 143
Officers Mr. David Sandoval Senior Vice President, General Counsel & Corporate Secretary Ms. Jill Mayer Senior Vice President of Human Resources Mr. Thomas Michael Ross Executive Vice President of Global Sales Mr. Jack Horgan Vice President of Corporate Development Mr. Douglas Arthur Doerfler Founder Mr. Ronald Evan Holtz CPA, Ph.D. Executive Vice President of Administration Mr. Maher Masoud President, Chief Executive Officer & Executive Director Dr. J. Stark Thompson Ph.D. Consultant Mr. Jay Gelfman Senior Vice President of Operations Mr. Douglas J. Swirsky CFA, CPA Chief Financial Officer